Abstract: The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with (i) an ACE inhibitor or a pharmaceutically acceptable salt thereof; or (II) an angiotensin II receptor blocker or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.

Abstract: A hybrid financial instrument, based on the traditional trust proffered structure, is designed to be more equity-like than debt-like. The financial instrument is designed to have permanence, ongoing payments, and loss absorption characteristics that meet rating agency requirements for favorable equity-like treatment.

Abstract: The real estate investment trust (“REIT”) structure and mechanism manages earnings distributions from the REIT to maintain REIT status. The REIT issues common stock to a bank affiliated parent (“holder”) in exchange for real estate related assets. The holder covenants to consent to consent dividends, under which the holder covenants to pay taxes on a consent dividend amount while the REIT deducts the consent dividend amount and retains the amount for each dividend period. The REIT also issues preferred securities to investors. At each dividend period, the REIT can declare cash dividends to preferred investors and/or declare consent dividends such that the REIT distributes at least a regulatory percentage of its annual income to preferred and common stockholders in order to maintain REIT status. The REIT is thus adequately capitalized, maintains status as a REIT, and receives stronger agency ratings, with regard to equity content, for the preferred securities.

Abstract: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.

Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one PDGF receptor tyrosine kinase inhibitor.

Abstract: The present is directed to a method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, PH, malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI, increase of formation of collagen and other extracellular matrix proteins, restenosis after stenting, PVD including PAD and peripheral venous disorders, CAD, morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), AF, renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, AIN, ATN, acute tubulo-interstitial nephritis, PKD, vascular inflammation, rennin secreting tumors, vasculitides or closure, restenosis of dialysis access grafts comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in combination wi

Abstract: The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with (i) an ACE inhibitor or a pharmaceutically acceptable salt thereof; or (II) an angiotensin II receptor blocker or a pharmaceutically acceptable salt thereof.

Abstract: A hybrid financial instrument, based on the traditional trust proffered structure, is designed to be more equity-like than debt-like. The financial instrument is designed to have permanence, ongoing payments, and loss absorption characteristics that meet rating agency requirements for favorable equity-like treatment.

Abstract: A substantially rectangularly shaped block of cementitious material has a metal reinforcing member extending there through and embedded therein. The reinforcing member has a height substantially equal to the height of the block and extends past one end of the block, terminating in an elongated T-shaped tongue. Adjacent the other end of the block, the reinforcing member terminates in an elongated groove, slightly larger than but complementary to the shape of the tongue. In use, adjacent blocks are loosely but securely locked together by the cooperating tongues and grooves of the reinforcing members of the adjoining building blocks.

Abstract: The production of a rennin of high milk coagulating activity and low proteolytic activity from a selected strain of Mucor miehei which is useful in cheese making.